MED20

Across TCGA pan-cancer cohorts, MED20 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MED20 data layer compared with 29 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MED20 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MED20 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, LSCC, and HNSC are the cancer types where MED20 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.630	1.000	.002	46	view →
LSCC	OS	Quartile	All	0.947	0.732	.015	10	view →
HNSC	DFS	Median	All	0.907	0.977	.033	3	view →
PDAC	OS	Median	II,III,IV	0.742	0.906	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MED20–CCRCC (DFS)

Open the CCRCC breakdown →